The ACROSS study: Long-term efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis.

ABSTRACT:

Background

In chronic diseases such as multiple sclerosis requiring lifelong treatment, studies on long-term outcomes are important.

Objective

To assess disability and magnetic resonance imaging-related outcomes in relapsing multiple sclerosis patients from a Phase 2 study of fingolimod 10 or more years after randomization and to compare outcomes in patients who had a higher fingolimod exposure versus those with a lower fingolimod exposure.

Methods

ACROSS was a cross-sectional follow-up study of patients originally enrolled in a Phase 2 fingolimod proof-of-concept study (NCT00333138). Disability and magnetic resonance imaging-related outcomes were assessed in patients grouped according to fingolimod treatment duration, based on an arbitrary cut-off: ≥8 years (high exp

SUBMITTER: Derfuss T 

PROVIDER: S-EPMC7132565 | biostudies-literature | 2020 Jan-Mar

REPOSITORIES: biostudies-literature